Publications by authors named "M H Kreuter"
During the COVID-19 pandemic the effectiveness of vaccines against SARS-CoV-2 in immunodeficient patients did not only affect the individual risk of these vulnerable patients but endangered the selection of new variants of concern due to prolonged virus shedding by these patients. In a tertiary center for pulmonary diseases, we investigated the immune response of 11 patients with primary humoral immunodeficiency and 13 healthy controls on the humoral and cellular level after full vaccination with a mRNA or vector vaccine against SARS-CoV-2. In the majority of patients (73%), we found antibodies against the Spike protein above the thresh-old of positivity.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to understand how various factors impact executive function (EF) impairments in individuals with type 2 diabetes, as EF issues can lead to worse health outcomes.
- Using baseline data from a Medicaid trial, researchers analyzed the relationships between EF and several demographic, health, and psychosocial factors through statistical methods.
- The findings highlighted six significant factors that correlate with EF impairment: age, education level, depression symptoms, comorbidity burden, diabetes-related distress, and future time orientation, emphasizing the importance of considering these when treating patients with diabetes.
Article Synopsis
- - The study explored the risk factors and consequences of acute exacerbations in patients with progressive fibrosing interstitial lung diseases (ILDs), using data from the INBUILD trial, which involved treatments with nintedanib versus placebo.
- - Results showed that 8.7% of patients experienced acute exacerbations, with lower lung function and older age being significant risk factors, while nintedanib treatment seemed to reduce the risk of these events.
- - The analysis indicated that acute exacerbations are linked to high mortality rates, with approximately 19% of patients at risk of death within 30 days following such events.
Article Synopsis
- Pulmonary lymphangiomatosis (PL) is an extremely rare lung disease marked by abnormal lymphatic growth, with no established diagnostic or treatment guidelines, prompting a study to gather patient data.
- The study reviewed 12 patients diagnosed from 1996 to 2022, noting that most were younger women, non-smokers, and commonly experienced symptoms like difficulty breathing and coughing up blood or lymphatic fluid, with severe impacts on lung function.
- Treatment with sirolimus resulted in significant improvements for patients, although further research is needed to fully understand the disease and develop comprehensive treatment strategies.
This plain language summary shares results from a clinical study called INTEGRIS-IPF that was published in the in 2024. This study looked at a medicine called (beck-so-teh-grast) as a possible treatment for (i-dee-uh-pa-thick pul-muh-ner-ee fie-bro-sis; IPF). is an investigational medicine, which means that it is being studied and has not yet been approved by the US Food and Drug Administration (FDA), for people with IPF to take as a treatment.
View Article and Find Full Text PDF